Research programme: antiviral immunostimulants - Kineta

Drug Profile

Research programme: antiviral immunostimulants - Kineta

Alternative Names: CB 183872; IB 657; LHF-535; rOAS-1

Latest Information Update: 23 Jan 2015

Price : $50

At a glance

  • Originator Illumigen Biosciences
  • Developer Kineta; KPI Therapeutics
  • Class Enzymes; Ligases; Proteins
  • Mechanism of Action Immunostimulants; Ribonuclease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections

Most Recent Events

  • 21 Jan 2015 Cubist Pharmaceuticals has been acquired by Merck & Co
  • 05 Jun 2014 Kineta and KPI Therapeutics agree to co-develop Antiviral immunostimulants
  • 30 Oct 2010 rOAS 1 licensed to Kineta in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top